Multicomponent therapeutics for networked systems
The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
Therapeutic regimens that comprise more than one active ingredient are commonly used in clinical medicine. Despite this, most drug discovery efforts search for drugs that are composed of a single chemical entity. A focus in the early drug discovery process on identifying and optimizing the activity of combinations of molecules can result in the identification of more effective drug regimens. A systems perspective facilitates an understanding of the mechanism of action of such drug combinations.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“combinations of chemical agents (or manipulations such as those of transcription factors that affect multiple steps in a pathway [1906] or modulation of multiple gene products [2311], or both [2312,2313]) will be far more efficacious, for instance in modulating iron-catalysed oxidative stress and its sequelae, than will be the use of 'magic bullet' single agents.”
From Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases (2009) · cites this paper as [1705]
Citations
Cites
Cancer: Principles and Practice of Oncology.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-819_4 · Cited by 8,516
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178 · cited 1×
“There have been attempts to systematize a set of principles that can account for combination drugs that exist toda”
BackgroundLessons from hereditary colorectal cancer
Kinzler, K. W., & Vogelstein, B. (1996) · Cell · doi:10.1016/s0092-8674(00)81333-1 · Cited by 4,919
Systems biology: a brief overview
Kitano, H. (2002) · Science · doi:10.1126/science.1069492 · Cited by 4,265 · cited 1×
“Systems biology is the large-scale study of the functional and physical relationships between the molecules that make up lif”
BackgroundBlume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738
Transcriptional Regulatory Networks in Saccharomyces cerevisiae
Lee, T. I., Rinaldi, N. J., Robert, F., Odom, D. T., Bar-Joseph, Z., Gerber, G. K., Hannett, N. M., Harbison, C. T., Thompson, C. M., Simon, I., et al. (2002) · Science · doi:10.1126/science.1075090 · Cited by 2,956
THE TOXICITY OF POISONS APPLIED JOINTLY1
BLISS, C. I. (1939) · Annals of Applied Biology · doi:10.1111/j.1744-7348.1939.tb06990.x · Cited by 2,419 · cited 1×
“Numerous researchers have attempted to provide an unambiguous framework for the calculation of additive effects between compounds; these approaches are reviewed comprehensively elsewher”
BackgroundSystematic Genetic Analysis with Ordered Arrays of Yeast Deletion Mutants
Tong, A. H. Y., Evangelista, M., Parsons, A. B., Xu, H., Bader, G. D., Pagé, N., Robinson, M., Raghibizadeh, S., Hogue, C. W. V., Bussey, H., et al. (2001) · Science · doi:10.1126/science.1065810 · Cited by 2,138
A N EW A PPROACH TO D ECODING L IFE : Systems Biology
Ideker, T., Galitski, T., & Hood, L. (2001) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.2.1.343 · Cited by 1,664 · cited 1×
“Systems biology is the large-scale study of the functional and physical relationships between the molecules that make up lif”
BackgroundDolma, S., Lessnick, S. L., Hahn, W. C., & Stockwell, B. R. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00050-3 · Cited by 1,446
Self-citation
Research works printed but not linked: 2
- Ehrlich, P. Chemotherapeutics: scientific principles, methods and results. Lancet 2, 445–451 (1913).
- Albert, A. Selective Toxicity (Methuen & Co., London, 1968).
Cited by
Items 301–400 of 799
Tempo and mode of inhibitor–mutagen antiviral therapies: A multidisciplinary approach
Iranzo, J., Perales, C., Domingo, E., & Manrubia, S. C. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1110489108 · Cited by 37
“A 1⁄4 iβ 0 iðα− βÞ α ; [6]”
Building a drug–target network and its applications
Lee, S., Park, K., & Kim, D. (2009) · Expert Opinion on Drug Discovery · doi:10.1517/17460440903322234 · Cited by 39
“This combination is needed because such targets are difficult to detect by experimental technique alone, making it more difficult to uncover the complex mode of drug actions [72,73] .”
BackgroundChen, G., Gong, R., Shi, X., Yang, D., Zhang, G., Lü, A., Yue, J., & Bian, Z. (2016) · Oncotarget · doi:10.18632/oncotarget.10367 · Cited by 37
“Consequently, in the pharmacological industry, there is a shift from developing drugs specifically targeting single signaling pathway or protein to combination therapies that consist of more than one active ingredients targeting multiple signaling pathways or proteins [22].”
BackgroundShin, S., Müller, A., Verma, N., Lev, S., & Nguyen, L. K. (2018) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1006192 · Cited by 38
Rickles, R. J., Pierce, L. T., Giordano, T. P., Tam, W. F., McMillin, D. W., Delmore, J. E., Laubach, J. P., Borisy, A. A., Richardson, P. G. G., & Lee, M. S. (2010) · Blood · doi:10.1182/blood-2009-11-252668 · Cited by 41
Self-citationPhenolic composition and in vitro activity of the Brazilian fruit tree Caryocar coriaceum Wittm.
Araruna, M. K. A., Santos, K. K. A., da Costa, J. G. M., Coutinho, H. D. M., Boligon, A. A., Stefanello, S. T., Athayde, M. L., Saraiva, R. D. A., da Rocha, J. B. T., Kerntopf, M. R., et al. (2012) · European Journal of Integrative Medicine · doi:10.1016/j.eujim.2012.11.007 · Cited by 36
An assessment of the evidence for antibacterial activity of stinging nettle (Urtica dioica) extracts
Harrison, F., Furner-Pardoe, J., & Connelly, E. N. (2022) · Access Microbiology · doi:10.1099/acmi.0.000336 · Cited by 36
Development of rat urinary HPLC-UV profiling for metabonomic study on Liuwei Dihuang Pills
Xie, B., Gong, T., Gao, R., Liu, J., Zuo, J., Wang, X., & Zhang, Z. (2008) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2008.10.022 · Cited by 36
Human Disease and Drug Pharmacology, Complex as Real Life
Viayna, E., Sola, I., Pietro, O. D., & Muñoz‐Torrero, D. (2013) · Current Medicinal Chemistry · doi:10.2174/0929867311320130002 · Cited by 39
“Some experimental and theoretical methods are being developed for designing optimal drug combinations for therapeutic use, with minimized problems associated with drug-drug interactions [76,125-128].”
BackgroundHaaland, I., Opsahl, J. A., Berven, F. S., Reikvam, H., Fredly, H., Haugse, R., Thiede, B., McCormack, E., Laín, S., Bruserud, Ø., et al. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-116 · Cited by 38
“Determination of drug interaction by Bliss independence analysis assumes that the two drugs act through independent mechanisms [34]; nutlin-3 acts as an MDM2 inhibitor, and geldanamycin binds to and inhibits Hsp90 (although the may converge on the same pathway and indirectly affect the same down stream targets).”
BackgroundFan, M., Jin, C., Li, D., Deng, Y., Lin, Y., Chen, Y., Ma, Y., & Wang, T. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1289901 · Cited by 37
Polyactives: controlled and sustained bioactive release via hydrolytic degradation
Stebbins, N. D., Faig, J. J., Yu, W., Guliyev, R., & Uhrich, K. E. (2015) · Biomaterials Science · doi:10.1039/c5bm00051c · Cited by 38
Shape and evolution of the fundamental niche in marine Vibrio
Materna, A. C., Friedman, J., Bauer, C., David, C., Chen, S., Huang, I. B., Gillens, A., Clarke, S. A., Polz, M. F., & Alm, E. J. (2012) · The ISME Journal · doi:10.1038/ismej.2012.65 · Cited by 43
“An analogous approach is widely used in multicomponent drug therapeutics (Keith et al., 2005; Yeh et al., 2006), where it is known as isobolographic analysis (Gessner, 1995).”
MethodKim, S., Lee, S., Kim, J.-K., Chung, H. J., & Jeon, J. S. (2019) · Biomicrofluidics · doi:10.1063/1.5066558 · Cited by 39
Histone deacetylases as an epigenetic pillar for the development of hybrid inhibitors in cancer
Stazi, G., Fioravanti, R., Mai, A., Mattevi, A., & Valente, S. (2019) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2019.03.002 · Cited by 35
Weiss, A., Roux-Bourdieu, M. L., Zoetemelk, M., Ramzy, G. M., Rausch, M., Harry, D., Miljkovic‐Licina, M., Falamaki, K., Wehrle‐Haller, B., Meraldi, P., et al. (2019) · Cancers · doi:10.3390/cancers11101612 · Cited by 35
Yadav, P. K., Saklani, R., Tiwari, A. K., Verma, S., Chauhan, D., Yadav, P., Rana, R., Kalleti, N., Gayen, J. R., Wahajuddin, W., et al. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123209 · Cited by 35
The neuroprotective mechanism of action of the multimodal drug ladostigil
Weinreb, O., Amit, T., Bar‐Am, O., Yogev‐Falach, M., & Youdim, M. B. H. (2008) · Frontiers in bioscience · doi:10.2741/3069 · Cited by 35
“Nonetheless, developing combination of therapy raises complexity of drug-drug interaction, dosage ranging and metabolic shunt effects more than are derived from a single multifunctional drug (75, 76).”
BackgroundSystems biology analysis of protein‐drug interactions
Colinge, J., Rix, U., Bennett, K. L., & Superti‐Furga, G. (2011) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201100077 · Cited by 36
“These in turn can interact with other pathways [7].”
BackgroundFangjiomics: In Search of Effective and Safe Combination Therapies
Wang, Z., Liu, J., Cheng, Y., & Wang, Y. (2011) · The Journal of Clinical Pharmacology · doi:10.1177/0091270010382913 · Cited by 35
Kim, S., Masum, F., Kim, J.-K., Chung, H. J., & Jeon, J. S. (2019) · Lab on a Chip · doi:10.1039/c8lc01406j · Cited by 37
Ikram, N., Mirza, M. U., Vanmeert, M., Froeyen, M., Salo‐Ahen, O. M. H., Tahir, M., Qazi, A. M., & Ahmad, S. (2019) · Biomolecules · doi:10.3390/biom9040124 · Cited by 36
“In order to improve the safety and resistance profiles, together with enhancing therapeutic efficacies, multi-target agents and drug combinations are highly sought after [67,73,74].”
BackgroundMeasuring higher-order drug interactions: A review of recent approaches
Tekin, E., Savage, V. M., & Yeh, P. J. (2017) · Current Opinion in Systems Biology · doi:10.1016/j.coisb.2017.05.015 · Cited by 38
Inulin-based formulations as an emerging therapeutic strategy for cancer: A comprehensive review
Ghali, E. N. H. K., Pranav, Chauhan, S. C., & Yallapu, M. M. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.129216 · Cited by 35
Assessment of anti-scarring therapies in ex vivo organ cultured rabbit corneas
Sriram, S., Gibson, D. J., Robinson, P. M., Pi, L., Tuli, S. S., Lewin, A. S., & Schultz, G. S. (2014) · Experimental Eye Research · doi:10.1016/j.exer.2014.06.014 · Cited by 33
“It is also less vulnerable to acquired resistance as the system is less able to compensate for the action of two or more drugs simultaneously (Borisy et al., 2003; Keith et al., 2005).”
Chang, H.-N., Pang, J. S., Yang, S., Hung, C., Chiang, C.-H., Lin, T., & Lin, Y. (2010) · Molecules · doi:10.3390/molecules15096423 · Cited by 33
Brullo, C., Spisani, S., Selvatici, R., & Bruno, O. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.11.031 · Cited by 33
Design and Development of IKZF2 and CK1α Dual Degraders
Miyamoto, D. K., Curnutt, N. M., Park, S., Stavropoulos, A., Kharas, M. G., & Woo, C. M. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01736 · Cited by 35
Shaaban, A. E., Ali, A. R., Ayyad, S.-E. N., & Badria, F. A. A.-R. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.108075 · Cited by 36
Zhou, S., Li, Y., & Hou, T. (2013) · Journal of Chemical Information and Modeling · doi:10.1021/ci400065e · Cited by 32
Triclosan-caffeic acid hybrids: Synthesis, leishmanicidal, trypanocidal and cytotoxic activities
Otero, E., García, E., Palacios, G., Yepes, L. M., Cardá, M., Agut, R., Vélez, I. D., Cardona‐Galeano, W., & Robledo, S. M. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.09.064 · Cited by 32
Neurokinin-1 receptor-based bivalent drugs in pain management: The journey to nowhere?
Kleczkowska, P., Nowicka, K., Bujalska‐Zadrożny, M., & Hermans, E. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.11.007 · Cited by 34
Hong, Z., Xie, J., Hu, H., Bai, Y., Hu, X., Li, T., Chen, J., Sheng, J., & Tian, Y. (2023) · Journal of Future Foods · doi:10.1016/j.jfutfo.2023.03.009 · Cited by 37
Fang, P., Elena, A., Kunath, M. A., Berendonk, T. U., & Klümper, U. (2023) · ISME Communications · doi:10.1038/s43705-023-00262-4 · Cited by 32
Interaction of baicalin with berberine for glucose uptake in 3T3-L1 adipocytes and HepG2 hepatocytes
Zhang, C., Yu, R., Liu, Y., Tu, X.-Y., Tu, J., Wang, Y., & Xu, G. (2013) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2013.11.054 · Cited by 32
Cyclic nucleotide-based therapeutics for chronic obstructive pulmonary disease
Giembycz, M. A., & Maurice, D. H. (2014) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2014.04.001 · Cited by 34
Learning the drug target‐likeness of a protein
Xu, H., Xu, H., Lin, M., Wang, W., Li, Z., Huang, J., Chen, Y., & Chen, X. (2007) · PROTEOMICS · doi:10.1002/pmic.200700062 · Cited by 33
Lv, X., Guoying, D., Lv, G., Chen, Y., Wu, Y., Shen, H., & Xu, H. (2016) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2016.03.017 · Cited by 31
Garmaroudi, F. S., Handy, D. E., Liu, Y., & Loscalzo, J. (2016) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1004822 · Cited by 31
“pharmacology logically in order to replace the one-gene, one-protein, and one-mechanism perspective with a systems-oriented paradigm to improve the therapeutic index of potential drugs targeting these complex diseases [26, 27].”
BackgroundJenny, M., Schwaiger, W., Bernhard, D., Wrulich, O. A., Cosaceanu, D., Fuchs, D., & Ueberall, F. (2005) · Journal of Carcinogenesis · doi:10.1186/1477-3163-4-15 · Cited by 31
“(Nature Reviews, Drug Discovery, 2005) [20] that a focus on multicomponent therapeutics might lead to new insights in drug discovery and that multifactorial therapeutics are necessary for the treatment of multifactorial diseases.”
Tomasetti, M., Strafella, E., Staffolani, S., Santarelli, L., Neužil, J., & Guerrieri, R. A. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605617 · Cited by 32
“Drug combination is a promising strategy to overcome side-effects associated with high doses of single drugs (Keith et al, 2005; Lehár et al, 2009).”
BackgroundKinase Control Prevents HIV-1 Reactivation in Spite of High Levels of Induced NF-κB Activity
Wolschendorf, F., Bosque, A., Shishido, T., Duverger, A. E., Jones, J. L., Planelles, V., & Kutsch, O. (2012) · Journal of Virology · doi:10.1128/jvi.06726-11 · Cited by 34
“The idea to combine drugs (multidrug combinations for networked systems) (39) has already been applied in some previous studies looking into the ability of drug combinations to reactivate latent HIV-1 infection in experimental systems (22, 56).”
ResultNucleic acid combinations: A new frontier for cancer treatment
Remant Bahadur, K. C., Thapa, B., Valencia‐Serna, J., Aliabadi, H. M., & Uludağ, H. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.04.029 · Cited by 32
Hii, L., Lim, S. E., Leong, C., Chin, S.-Y., Tan, N. P., Lai, K., & Mai, C. (2019) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-019-2663-9 · Cited by 30
Synergistic Effect of L-Carnosine and EGCG in the Prevention of Physiological Brain Aging
Davinelli, S., Marco, R. D., Bracale, R., Quattrone, A., Zella, D., & Scapagnini, G. (2013) · Current Pharmaceutical Design · doi:10.2174/1381612811319150007 · Cited by 32
In vitro studies of berberine metabolism and its effect of enzyme induction on HepG2 cells
Cui, H., Zhang, Q., Wang, J., Chen, J., Zhang, Y., & Tong, X. (2014) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2014.10.018 · Cited by 31
Qu, C., Wang, L., Jin, W., Tang, Y., Jin, Y., Shi, X.-Q., Shang, L.-L., Shang, E., & Duan, J. (2016) · Molecules · doi:10.3390/molecules21111480 · Cited by 30
“With the accumulation of the therapeutic experience, many traditional Chinese medicine (TCM) practitioners realized that the pathogenesis and progression of diseases are complicated and the effect of a single drug may be modest and/or hampered by various side effects or resistance in the clinic [4].”
BackgroundThe recent progress of deep-learning-based in silico prediction of drug combination
Liu, H., Fan, Z., Lin, J., Yang, Y., Ran, T., & Chen, H. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103625 · Cited by 32
Mohamed, A. M., Abou‐Ghadir, O. F., Mostafa, Y. A., Dahlous, K. A., Bräse, S., & Youssif, B. G. M. (2024) · Frontiers in Chemistry · doi:10.3389/fchem.2024.1447618 · Cited by 29
Zhao, J., Zhang, X., & Zhang, S. (2014) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2013.79 · Cited by 32
A systems biology analysis of autophagy in cancer therapy
Shi, Z., Li, C., Zhao, S., Yu, Y., An, N., Liu, Y.-X., Wu, C., Yue, B., & Bao, J. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.06.004 · Cited by 35
“rial treatment is a promising way for future cancer therapies to be developed [146–148].”
BackgroundVISAGE Reveals a Targetable Mitotic Spindle Vulnerability in Cancer Cells
Patterson, J. C., Joughin, B. A., Prota, A. E., Mühlethaler, T., Jonas, O. H., Whitman, M. A., Varmeh, S., Chen, S., Balk, S. P., Steinmetz, M. O., et al. (2019) · Cell Systems · doi:10.1016/j.cels.2019.05.009 · Cited by 29
“Publish This is an open access article under the CC BY license (http://creative cer cell selectivity, reducing the development of resistance, and allowing for decreases in individual drug dosage, possibly avoiding toxicity (Keith et al., 2005; Lehár et al., 2009).”
BackgroundTherapeutic significance of molecular hybrids for breast cancer research and treatment
Shagufta, & Ahmad, I. (2022) · RSC Medicinal Chemistry · doi:10.1039/d2md00356b · Cited by 29
Williams, M. J. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.08.019 · Cited by 34
More accurate matrix-matched quantification using standard superposition method for herbal medicines
Liu, Y., Shi, X., Liu, E., Sheng, L., Qi, L., & Li, P. (2012) · Journal of Chromatography A · doi:10.1016/j.chroma.2012.07.020 · Cited by 29
Counteracting antibiotic resistance: breaking barriers among antibacterial strategies
Baquero, F., Coque, T. M., & Cantón, R. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.925881 · Cited by 30
“Certainly a conceptual revision is needed, considering not only the many dimensions of the host--pathogen interactions during the infection, leading to multicomponent therapeutics [40,41], but also that the infective process goes beyond the individual patient, and that a ‘sick, infected environment with resistant bact…”
BackgroundBelizário, J. E., Sangiuliano, B. A., Pérez-Sosa, M., Neyra, J. M., & Moreira, D. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00312 · Cited by 29
“Nonetheless, predictive models for the complex combination of genetic alterations and biochemical pathways that translate in drug sensitivity and resistance in real solid tumors remain a challenge (Keith et al., 2005; Yang et al., 2010; Domcke et al., 2013; Covell, 2015).”
BackgroundKawaguchi, K., Igarashi, K., Miyake, K., Lwin, T. M., Miyake, M., Kiyuna, T., Hwang, H. K., Murakami, T., DeLong, J. C., Singh, S. R., et al. (2018) · Tissue and Cell · doi:10.1016/j.tice.2018.05.003 · Cited by 30
Cho, H., Shen, Q. “., Zhang, L. H., Okumura, M., Kawakami, A., Ambrose, J., Sigoillot, F. D., Miller, H., Gleim, S., Cobos‐Correa, A., et al. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.03.004 · Cited by 30
Systematic Review of Polyherbal Combinations Used in Metabolic Syndrome
Palla, A. H., Amin, F., Fatima, B., Shafiq, A., Rehman, N. U., Haq, I. U., & Gilani, A. H. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.752926 · Cited by 32
Zhao, Y., Cheng, G., Hao, H., Pan, Y., Liu, Z., Dai, M., & Yuan, Z. (2016) · BMC Veterinary Research · doi:10.1186/s12917-016-0812-7 · Cited by 28
“Synergistic and additive combinations of two or more agents can overcome toxicity and other side effects associated with high doses of single drugs by countering biological compensation, allowing reduced dosage of each compound or accessing context-specific multitarget mechanisms [38, 39].”
BackgroundZhao, Y., Wang, M., Tsering, J., Li, H., Li, S., Li, Y., Liu, Y., & Hu, X. (2018) · Integrative Cancer Therapies · doi:10.1177/1534735418774410 · Cited by 28
“Although there is a lack of specific data to elucidate the antineoplastic effect of Triphala against gynecological tumors, emerging studies have reported that a few of its constituents (gallic acid, ellagic acid, chebulic acid, and their derivatives, flavonoids, ascorbic acid, and others) have such properties.(8,9) Be…”
BackgroundWang, A., Xu, H., & Ding, X. (2020) · Advanced Therapeutics · doi:10.1002/adtp.201900135 · Cited by 28
Benzimidazole–ibuprofen/mesalamine conjugates: Potential candidates for multifactorial diseases
Bansal, Y., Kaur, M., & Silakari, O. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.10.081 · Cited by 30
Chen, X., Pei, L., & Lu, J. (2013) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2013.01.001 · Cited by 27
Cheng, B., Hou, Y., Wang, L., Dong, L., Peng, J., & Bai, G. (2012) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-012-6332-9 · Cited by 27
Bizzarri, M., Fedeli, V., Monti, N., Cucina, A., Jalouli, M., Alwasel, S. H., & Harrath, A. H. (2021) · The EPMA Journal · doi:10.1007/s13167-021-00254-1 · Cited by 31
4-aminoquinoline analogues and its platinum (II) complexes as antimalarial agents
de Souza, N. B., Carmo, A. M. L., Lagatta, D. C., Alves, M. J. M., Fontes, A. P. S., Coimbra, E. S., da Silva, A. D., & Abramo, C. (2011) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2011.03.003 · Cited by 27
Regulation of Inflammation-Mediated Chronic Diseases by Botanicals
Sung, B., Prasad, S., Gupta, S. C., Patchva, S., & Aggarwal, B. B. (2012) · Advances in botanical research · doi:10.1016/b978-0-12-394591-4.00003-9 · Cited by 33
Ueberall, F., Fuchs, D., & Vennos, C. (2006) · Forschende Komplementärmedizin / Research in Complementary Medicine · doi:10.1159/000090669 · Cited by 27
Predicting and characterizing selective multiple drug treatments for metabolicdiseases and cancer
Facchetti, G., Zampieri, M., & Altafini, C. (2012) · BMC Systems Biology · doi:10.1186/1752-0509-6-115 · Cited by 27
“However, even though both the financial burden of conducting trials as well as the risk of adverse events in trial populations is expected to be sensibly lower for already approved drugs, so far the experimental investigations of multicomponent therapies have been quite limited [4,5].”
BackgroundGostner, J. M., Wrulich, O. A., Jenny, M., Fuchs, D., & Ueberall, F. (2012) · BMC Complementary and Alternative Medicine · doi:10.1186/1472-6882-12-18 · Cited by 34
“This mechanistic view also explains why in many cases, the fractionation or isolation of principal constituents from extracts ends up with a loss of previously detected activities [15].”
BackgroundInfluentialHydroxyurea synergizes with valproic acid in wild-type p53 acute myeloid leukaemia
Leitch, C., Osdal, T., Andresen, V., Molland, M., Kristiansen, S., Nguyen, X. N., Bruserud, Ø., Gjertsen, B. T., & McCormack, E. (2016) · Oncotarget · doi:10.18632/oncotarget.6991 · Cited by 27
“Synergism was calculated by the Chou-Talalay method [40] or by Bliss Independence analysis [41].”
MethodXu, D., Chen, H., Mak, S., Hu, S., Tsim, K. W. K., Yuanjia, H., Sun, Y., Zhang, G., Wang, Y., Zhang, Z., et al. (2016) · Neurochemistry International · doi:10.1016/j.neuint.2016.07.006 · Cited by 27
Drug combinatorics and side effect estimation on the signed human drug-target network
Torres, N. B., & Altafini, C. (2016) · BMC Systems Biology · doi:10.1186/s12918-016-0326-8 · Cited by 27
Effects of hispolon on glioblastoma cell growth
Arcella, A., Oliva, M. A., Sanchez, M., Staffieri, S., Esposito, V., Giangaspero, F., & Cantore, G. (2017) · Environmental Toxicology · doi:10.1002/tox.22419 · Cited by 29
“Since the twentieth century, advances in Omics and Cell Biology have greatly impacted on the increasing use of drug combination in modern medicine.(38) The enhanced understanding of the biology of a disease as a disturbed system of interconnected molecular pathways which are more susceptible to the simultaneous action…”
BackgroundAnastasio, T. J. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00116 · Cited by 26
Parsimonious Discovery of Synergistic Drug Combinations
Severyn, B. S., Liehr, R. A., Wolicki, A., Nguyen, K. H., Hudak, E. M., Ferrer, M., Caldwell, J. S., Hermes, J. D., Li, J., & Tudor, M. (2011) · ACS Chemical Biology · doi:10.1021/cb2003225 · Cited by 29
de Oliveira, E. A., de Lima, D. S., Cardozo, L. E., de Souza, G. F., de Souza, N., Alves-Fernandes, D. K., Faião‐Flores, F., Quincoces, J., Barros, S. B. D. M., Nakaya, H. I., et al. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.08.018 · Cited by 29
Medicinal polypharmacology—a scientific glossary of terminology and concepts
Stefan, S. M., & Rafehi, M. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1419110 · Cited by 28
“…disease networks that result in feedback, crosstalk, and, subsequently, therapy resistance (Morphy and Rankovic, 2007; Azmi and Mohammad, 2014; Keith et al., 2005); (iii) Multitargeticity is an inherent character of small molecules that has molecular-structural limits (Paolini et al., 2006;…”
BackgroundLi, J., Wu, R., Meng, F., Wang, Z., Wang, C., Wang, Y., & Zhang, Z. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045811 · Cited by 25
“[6,23].”
Wang, Z., Wan, H., Tong, X., He, Y. T., Yang, J., Zhang, L., Shao, C., Ding, Z., Wan, H., & Li, C. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111451 · Cited by 26
Álvarez-Córdoba, M., Reche-López, D., Cilleros-Holgado, P., Talaverón-Rey, M., Villalón-García, I., Povea-Cabello, S., Suarez-Rivero, J. M., Suárez-Carrillo, A., Munuera-Cabeza, M., Piñero-Pérez, R., et al. (2022) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-022-02465-9 · Cited by 26
“The limitations of many monotherapies can be overcome by targeting disease pathomechanisms on multiple fronts [74].”
BackgroundBol, D. K., & Ebner, R. (2006) · Pharmacogenomics · doi:10.2217/14622416.7.2.227 · Cited by 25
“While this group chose to identify the single active agent in the mixture, many proven therapeutic procedures involve more than one active ingredient [33].”
BackgroundAntimicrobial, modulatory and chemical analysis of the oil of Croton limae
Leite, T. R., da Silva, M. A. P., SANTOS, A. C. B. D., Coutinho, H. D. M., Duarte, A. E., & da Costa, J. G. M. (2017) · Pharmaceutical Biology · doi:10.1080/13880209.2017.1355926 · Cited by 25
“The swift evolution of resistance to antimicrobials and the lack of discovery of new drugs have motivated the search for alternatives, such as multidrug treatment approaches (Keith et al. 2005).”
BackgroundClose, D. A., Wang, A. X., Kochanek, S. J., Shun, T., Eiseman, J. L., & Johnston, P. A. (2018) · SLAS DISCOVERY · doi:10.1177/2472555218812429 · Cited by 26
Lu, Y., Chen, J., Fan, N., Song, W., Sheng, H., Yang, Y., & Wang, J. (2026) · npj Digital Medicine · doi:10.1038/s41746-026-02400-3 · Cited by 27
Zhu, T. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.562660 · Cited by 24
Ou, Q.-Q., Qian, X.-H., Li, D., Zhang, Y.-X., Pei, X.-N., Chen, J., & Li, Y. (2015) · Pediatric Research · doi:10.1038/pr.2015.252 · Cited by 24
Active-targeting docetaxel-loaded mixed micelles for enhancing antitumor efficacy
Shi, C., Zhang, Z., Wang, F., & Luan, Y. (2018) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2018.05.039 · Cited by 24
The pharmaceutical multi-activity of metallofullerenol invigorates cancer therapy
Li, J., Chen, L., Su, H., Yan, L., Gu, Z., Chen, Z., Zhang, A., Zhao, F., & Zhao, Y. (2019) · Nanoscale · doi:10.1039/c9nr04129j · Cited by 25
Evaluation of a curcumin-containing mucoadhesive film for periodontal postsurgical pain control
Gujjari, S. K., Anil, A., & Venkatesh, M. P. (2019) · Journal of Indian Society of Periodontology · doi:10.4103/jisp.jisp_700_18 · Cited by 24
“[8] In addition to this, it is also highly economical, is easily available, and has a multitargeted mode of action on the various molecular signaling pathways, unlike NSAIDs.[28]”
Do Biologically Relevant Compounds Have More Chance To Be Drugs?
De, K., Ren, W., Lu, W. P., & Zhang, H. (2009) · Journal of Chemical Information and Modeling · doi:10.1021/ci900229c · Cited by 24
A polymer–(multifunctional single-drug) conjugate for combination therapy
Zhou, D., He, S., Cong, Y., Xie, Z., Chen, X., Jing, X., & Huang, Y. (2015) · Journal of Materials Chemistry B · doi:10.1039/c5tb00576k · Cited by 23
Promiscuous modulation of ion channels by anti-psychotic and anti-dementia medications
Bianchi, M. T. (2009) · Medical Hypotheses · doi:10.1016/j.mehy.2009.09.003 · Cited by 26
“Classic theories of brain dysfunction that emphasize single neurotransmitter systems are gradually giving way to so-called ‘‘network” pathophysiology [1–7].”
Schmidt, L., Kling, T., Monsefi, N., Olsson, M. M., Hansson, C., Baskaran, S., Lundgren, B., Märtens, U., Häggblad, M., Westermark, B., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not111 · Cited by 27
Using small molecules to overcome drug resistance induced by a viral oncogene
Smukste, I., Bhalala, O. G., Persico, M., & Stockwell, B. R. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.01.012 · Cited by 25
“The Bliss independence model predicts the combined response C for two single compounds with effects A and B according to the relationship C = A + B 2 A*B and represents one of the most stringent requirements for synergy (Keith et al., 2005).”
BackgroundSelf-citationEnhanced cytotoxicity by a benzothiazole-containing cisplatin derivative in breast cancer cells
You, C., Yu, J., Sun, Y., Luo, Y., Zhang, X., Zhu, J. W., & Sun, B. (2017) · New Journal of Chemistry · doi:10.1039/c6nj02753a · Cited by 22
Aguayo‐Morales, H., Rivera, C. A. S., Claudio‐Rizo, J. A., & Cobos-Puc, L. E. (2023) · Pharmaceuticals · doi:10.3390/ph16040514 · Cited by 22
“In both cases, triton treatment reduced the proliferation of both cell types, suggesting that skin fibroblasts are more sensitive than macrophages to some compounds of the extract that modulate biological targets involved in the viability or proliferation phenomena [43].”
BackgroundPro-apoptotic and anticancer properties of Thapring – A Tibetan herbal formulation
Choedon, T., Dolma, D., & Kumar, V. (2011) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2011.05.031 · Cited by 22
Metadata
- Authors
- Keith, C. T., Borisy, A. A., & Stockwell, B. R.
- Affiliations
- Columbia University (US)
- Corresponding author
- Keith, Curtis T.
- Borisy, Alexis A.
- Stockwell, Brent R.
- ORCID
- Stockwell, Brent R.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2005-01
- Volume
- 4
- Issue
- 1
- Pages
- 71-78
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1592483428
- Cited by
- 769
- References
- 67
- Citations by year
- 2026: 13 · 2025: 24 · 2024: 30 · 2023: 33 · 2022: 44 · 2021: 36 · 2020: 34 · 2019: 36 · 2018: 42 · 2017: 29 · 2016: 43 · 2015: 51 · 2014: 55 · 2013: 49 · 2012: 47
- FWCI
- 3.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Burroughs Wellcome Fund
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene Regulatory Network Analysis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
- Keywords
- combination therapy, systems biology, mechanism of action, drug discovery
- MeSH terms
- Clinical Trials as Topic, Drug Synergism, Drug Therapy, Combination, Humans, Terminology as Topic, Drug Design
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.